---
document_datetime: 2025-12-02 05:07:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme.html
document_name: aldurazyme.html
version: success
processing_time: 0.1119569
conversion_datetime: 2025-12-26 20:28:48.662194
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Aldurazyme

[RSS](/en/individual-human-medicine.xml/65951)

##### Authorised

This medicine is authorised for use in the European Union

laronidase Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Aldurazyme](#more-information-on-aldurazyme-569)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Aldurazyme. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aldurazyme.

Expand section

Collapse section

## What is Aldurazyme?

Aldurazyme is a solution for infusion (drip) into a vein that contains the active substance laronidase.

## What is Aldurazyme used for?

Aldurazyme is used in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; ? L iduronidase deficiency) to treat the non-neurological symptoms of the disease (symptoms that are not connected with the brain or nerves). MPS I is a rare, inherited disease, in which the level of ? L iduronidase enzyme activity is much lower than normal. This means that substances called glycosaminoglycans (GAGs) are not broken down, so they build up in most of the organs in the body and damage them. The non-neurological symptoms of MPS I can be an enlarged liver, stiff joints that make moving more difficult, reduced lung volume, heart disease and eye disease.

The medicine can only be obtained with a prescription.

## How is Aldurazyme used?

Aldurazyme treatment should be supervised by a doctor who has experience in the management of patients with MPS I or other inherited metabolic diseases. Aldurazyme should be given in a hospital or clinic where resuscitation equipment is available, and patients may need to receive some medicines before the infusion to prevent an allergic reaction. Aldurazyme is given once a week as an infusion into a vein. It is intended for long-term use.

## How does Aldurazyme work?

The active substance in Aldurazyme, laronidase, is a copy of the human enzyme ? L iduronidase. It is produced by a method known as 'recombinant DNA technology': the enzyme is made by cells into which a gene (DNA) has been introduced that makes them able to produce laronidase. Laronidase is used as 'enzyme replacement therapy', which means that it replaces the enzyme that is missing in patients with MPS I. This controls the symptoms of MPS I, improving the patient's quality of life.

## How has Aldurazyme been studied?

Aldurazyme has been compared with placebo (a dummy treatment) in 45 patients aged six years and over with a confirmed diagnosis of MPS I. The main measure of effectiveness was the forced vital capacity (FVC, a measure of how well the lungs are working) and the distance the patients could walk over six minutes. These were measured before and after 26 weeks of treatment. After this, the study continued for up to four years and all of the patients were treated with Aldurazyme.

Aldurazyme has also been studied in 20 children below the age of five years who received Aldurazyme for a year. The study was looking mainly at the safety of the medicine, but it also measured its ability to reduce the levels of GAGs in the urine and the size of the liver.

## What benefit has Aldurazyme shown during the studies?

The study showed that Aldurazyme had improved both the FVC and the walking ability of patients at 26 weeks. This effect was maintained for up to four years.

In children under five years of age, Aldurazyme reduced the levels of GAGs in the urine by about 60%. Half of the children treated had a normal size liver at the end of the study.

## What is the risk associated with Aldurazyme?

Most of the side effects seen with Aldurazyme are reactions caused by the infusion procedure rather than the medicine itself. Some of these are severe, but the number of side effects tends to decrease with time. The most common side effects in patients over the age of five years (seen in more than 1 patient in 10) are headache, nausea (feeling sick), abdominal pain (stomach ache), rash, arthropathy (damage to the joints), arthralgia (joint pain), back pain, pain in the extremities (hands and feet), flushing, pyrexia (fever) and reactions at the site of the infusion. In patients under five years of age, the most common side effects (seen in more than 1 patient in 10) are increased blood pressure, decreased oxygen saturation (a measure of how well the lungs are working), tachycardia (rapid heart rate), pyrexia and chills. For the full list of all side effects reported with Aldurazyme, see the package leaflet.

Almost all patients who receive Aldurazyme develop antibodies (proteins that are produced in response to Aldurazyme). The effect of these on the safety and effectiveness of the medicine is not fully known.

Aldurazyme must not be used in people who are severely allergic to laronidase or any of the other ingredients.

## Why has Aldurazyme been approved?

The CHMP decided that Aldurazyme gives effective control of the symptoms of MPS I. The Committee decided that Aldurazyme's benefits are greater than its risks and recommended that Aldurazyme be given marketing authorisation.

Aldurazyme was originally authorised under 'exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval. As the company had supplied the additional information requested, the 'exceptional circumstances' ended on 16 December 2015.

## Other information about Aldurazyme

The European Commission granted a marketing authorisation valid throughout the European Union for Aldurazyme on 10 June 2003.

For more information about treatment with Aldurazyme, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Aldurazyme : EPAR - Summary for the public

English (EN) (87.49 KB - PDF)

**First published:** 27/07/2009

**Last updated:** 11/02/2016

[View](/en/documents/overview/aldurazyme-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-435)

български (BG) (126.51 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/bg/documents/overview/aldurazyme-epar-summary-public_bg.pdf)

español (ES) (86.82 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/es/documents/overview/aldurazyme-epar-summary-public_es.pdf)

čeština (CS) (101.76 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/cs/documents/overview/aldurazyme-epar-summary-public_cs.pdf)

dansk (DA) (86.72 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/da/documents/overview/aldurazyme-epar-summary-public_da.pdf)

Deutsch (DE) (89.94 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/de/documents/overview/aldurazyme-epar-summary-public_de.pdf)

eesti keel (ET) (86.02 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/et/documents/overview/aldurazyme-epar-summary-public_et.pdf)

ελληνικά (EL) (108.13 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/el/documents/overview/aldurazyme-epar-summary-public_el.pdf)

français (FR) (87.49 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/fr/documents/overview/aldurazyme-epar-summary-public_fr.pdf)

hrvatski (HR) (123.61 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/hr/documents/overview/aldurazyme-epar-summary-public_hr.pdf)

italiano (IT) (85.33 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/it/documents/overview/aldurazyme-epar-summary-public_it.pdf)

latviešu valoda (LV) (99.76 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/lv/documents/overview/aldurazyme-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.95 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/lt/documents/overview/aldurazyme-epar-summary-public_lt.pdf)

magyar (HU) (96.39 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/hu/documents/overview/aldurazyme-epar-summary-public_hu.pdf)

Malti (MT) (104.85 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/mt/documents/overview/aldurazyme-epar-summary-public_mt.pdf)

Nederlands (NL) (85.81 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/nl/documents/overview/aldurazyme-epar-summary-public_nl.pdf)

polski (PL) (102.55 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/pl/documents/overview/aldurazyme-epar-summary-public_pl.pdf)

português (PT) (86.64 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/pt/documents/overview/aldurazyme-epar-summary-public_pt.pdf)

română (RO) (99.75 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/ro/documents/overview/aldurazyme-epar-summary-public_ro.pdf)

slovenčina (SK) (101.32 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/sk/documents/overview/aldurazyme-epar-summary-public_sk.pdf)

slovenščina (SL) (94.23 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/sl/documents/overview/aldurazyme-epar-summary-public_sl.pdf)

Suomi (FI) (85.28 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/fi/documents/overview/aldurazyme-epar-summary-public_fi.pdf)

svenska (SV) (69.83 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

11/02/2016

[View](/sv/documents/overview/aldurazyme-epar-summary-public_sv.pdf)

Aldurazyme : EPAR - Risk-management-plan

English (EN) (502.38 KB - PDF)

**First published:** 28/02/2024

[View](/en/documents/rmp-summary/aldurazyme-epar-risk-management-plan_en.pdf)

## Product information

Aldurazyme : EPAR - Product information

English (EN) (433.69 KB - PDF)

**First published:** 27/07/2009

**Last updated:** 17/10/2024

[View](/en/documents/product-information/aldurazyme-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-183)

български (BG) (492.32 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/bg/documents/product-information/aldurazyme-epar-product-information_bg.pdf)

español (ES) (284.51 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/es/documents/product-information/aldurazyme-epar-product-information_es.pdf)

čeština (CS) (329.51 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/cs/documents/product-information/aldurazyme-epar-product-information_cs.pdf)

dansk (DA) (318.4 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/da/documents/product-information/aldurazyme-epar-product-information_da.pdf)

Deutsch (DE) (386.05 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/01/2025

[View](/de/documents/product-information/aldurazyme-epar-product-information_de.pdf)

eesti keel (ET) (273.57 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/et/documents/product-information/aldurazyme-epar-product-information_et.pdf)

ελληνικά (EL) (486.75 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/el/documents/product-information/aldurazyme-epar-product-information_el.pdf)

français (FR) (462.58 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/fr/documents/product-information/aldurazyme-epar-product-information_fr.pdf)

hrvatski (HR) (580.04 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/hr/documents/product-information/aldurazyme-epar-product-information_hr.pdf)

íslenska (IS) (349.55 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/is/documents/product-information/aldurazyme-epar-product-information_is.pdf)

italiano (IT) (428.75 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/it/documents/product-information/aldurazyme-epar-product-information_it.pdf)

latviešu valoda (LV) (360.35 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/lv/documents/product-information/aldurazyme-epar-product-information_lv.pdf)

lietuvių kalba (LT) (351.25 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/lt/documents/product-information/aldurazyme-epar-product-information_lt.pdf)

magyar (HU) (299.74 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/hu/documents/product-information/aldurazyme-epar-product-information_hu.pdf)

Malti (MT) (508.1 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/mt/documents/product-information/aldurazyme-epar-product-information_mt.pdf)

Nederlands (NL) (462.86 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/nl/documents/product-information/aldurazyme-epar-product-information_nl.pdf)

norsk (NO) (235.74 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/no/documents/product-information/aldurazyme-epar-product-information_no.pdf)

polski (PL) (436.67 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/pl/documents/product-information/aldurazyme-epar-product-information_pl.pdf)

português (PT) (134.98 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/pt/documents/product-information/aldurazyme-epar-product-information_pt.pdf)

română (RO) (528.92 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/ro/documents/product-information/aldurazyme-epar-product-information_ro.pdf)

slovenčina (SK) (440.11 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/sk/documents/product-information/aldurazyme-epar-product-information_sk.pdf)

slovenščina (SL) (329.55 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/sl/documents/product-information/aldurazyme-epar-product-information_sl.pdf)

Suomi (FI) (315.56 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/fi/documents/product-information/aldurazyme-epar-product-information_fi.pdf)

svenska (SV) (319.04 KB - PDF)

**First published:**

27/07/2009

**Last updated:**

17/10/2024

[View](/sv/documents/product-information/aldurazyme-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0090 09/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aldurazyme : EPAR - All Authorised presentations

English (EN) (58.59 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-875)

български (BG) (44.81 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/bg/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_bg.pdf)

español (ES) (57.99 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/es/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.63 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/cs/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (62.6 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/da/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (63.43 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/de/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.9 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/et/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.91 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/el/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_el.pdf)

français (FR) (57.33 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fr/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (74.07 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hr/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (60.13 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/is/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.12 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/it/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (82.49 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lv/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (80.8 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lt/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (70.43 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hu/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.82 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/mt/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.47 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/nl/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (61.07 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/no/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_no.pdf)

polski (PL) (84.32 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pl/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.56 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pt/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.82 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/ro/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.16 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sk/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (67.52 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sl/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (56.93 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fi/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.02 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sv/documents/all-authorised-presentations/aldurazyme-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aldurazyme Active substance laronidase International non-proprietary name (INN) or common name laronidase Therapeutic area (MeSH) Mucopolysaccharidosis I Anatomical therapeutic chemical (ATC) code A16AB05

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.

## Authorisation details

EMA product number EMEA/H/C/000477 Marketing authorisation holder

Sanofi B.V.

Paasheuvelweg 25

Opinion adopted 20/02/2003 Marketing authorisation issued 09/06/2003 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aldurazyme : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (240.58 KB - PDF)

**First published:** 27/07/2009

**Last updated:** 17/10/2024

[View](/en/documents/procedural-steps-after/aldurazyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Aldurazyme : EPAR - Procedural steps taken before authorisation

English (EN) (88.79 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 11/02/2016

[View](/en/documents/procedural-steps/aldurazyme-epar-procedural-steps-taken-authorisation_en.pdf)

Aldurazyme : EPAR - Scientific Discussion

English (EN) (328.14 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/aldurazyme-epar-scientific-discussion_en.pdf)

#### More information on Aldurazyme

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu301022) on 14 February 2001. Aldurazyme was withdrawn from the Community register of orphan medicinal products in June 2013 at the end of the 10-year period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/10/2024

## Share this page

[Back to top](#main-content)